Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: Efficacy and toxicity data from a retrospective study

Giuseppe Curigliano, G. Spitaleri, E. Magni, K. Lorizzo, O. De Cobelli, M. Locatelli, L. Fumagalli, L. Adamoli, M. Cossu Rocca, E. Verri, T. De Pas, E. Jereczek-Fossa, G. Martinelli, A. Goldhksch, F. Nolè

Research output: Contribution to journalArticlepeer-review

Abstract

We retrospectively reviewed medical charts of 54 patients who underwent orchidectomy for germ cell tumors (GCT) and received a regimen, given every 3 weeks, consisting of cisplatin 100 mg/m2 day 4 intravenous (i.v.), bleomycin 15 Units (U) day 1 i.v. push; bleomycin 10 U days 1-3 24 h i.v. continuous infusion (c.i.) and etoposide 100 mg/m2 days 1-5/i.v. (PEB). 53 of 54 patients achieved a complete remission without adjunctive surgery. At a median follow-up of 48.2 months (95%CI 41.7 - 54.8 months) all patients but one are alive with no evidence of disease recurrence. Patients receiving PEB experienced no pulmonary toxicity, nephrotoxicity nor neurological adverse events. PEB with c.i. bleomycin is an active regimen with a low rate of acute and late toxicity. The main limitations of our study are related to the retrospective analysis, the limited number of patients and the restricted follow-up time. A prolonged follow-up is necessary to evaluate long term toxicity and outcome.

Original languageEnglish
Pages (from-to)687-692
Number of pages6
JournalJournal of Chemotherapy
Volume21
Issue number6
Publication statusPublished - Dec 2009

Keywords

  • Bleomycin
  • Cisplatin
  • Etoposide
  • Germ cells testicular cancer

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Oncology
  • Pharmacology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: Efficacy and toxicity data from a retrospective study'. Together they form a unique fingerprint.

Cite this